DexCom (DXCM) vs Smith & Nephew SNATS (SNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
DexCom (DXCM) has outperformed Smith & Nephew SNATS (SNN) over the past year, gaining 24.5% versus a loss of 25.0%. Over five years, SNN leads with a -23.8% price change compared with -38.0% for DXCM. DexCom is the larger company by market cap ($31.85 billion vs $11.28 billion), about 2.8 times the size.
On valuation, Smith & Nephew SNATS trades at a lower forward P/E (11.2x vs 27.0x for DexCom). Smith & Nephew SNATS pays a dividend yielding 1.47%, while DexCom does not currently pay one. DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 10.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | SNN |
|---|---|---|
| Share price | $84.41 | $26.96 |
| Market cap | $31.85B | $11.28B |
| 1-day change | +0.13% | +0.26% |
| YTD return | +27.18% | -17.83% |
| 1-year return | +24.54% | -24.97% |
| 5-year return | -37.99% | -23.82% |
| P/E ratio (TTM) | 33.50 | 18.34 |
| Forward P/E | 26.99 | 11.18 |
| EPS (TTM) | $2.52 | $1.47 |
| Dividend yield | 0.00% | 1.47% |
| Annual dividend | $0.00 | $0.397 |
| Revenue (latest FY) | $4.66B | $6.16B |
| Revenue growth (YoY) | +15.60% | +6.09% |
| Net income (latest FY) | $836.30M | $625.00M |
| Gross margin | 60.10% | 68.01% |
| Operating margin | 19.56% | 12.88% |
| Net margin | 17.94% | 10.14% |
| 52-week high | $92.59 | $37.51 |
| 52-week low | $54.11 | $26.12 |
| Distance from 52-week high | -8.83% | -28.13% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +14.00% | +19.88% |
| Average volume | 4.43M | 1.65M |
| Shares outstanding | 377.36M | 418.52M |
| Employees | 11,000 | 17,000 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DexCom is about 2.8 times larger than Smith & Nephew SNATS by market value ($31.85B vs $11.28B).
- DXCM has outperformed SNN by 49.5 percentage points over the past year.
- DexCom trades at a higher earnings multiple (33.5x vs 18.3x trailing P/E).
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.47% vs 0.00%).
- DexCom is more profitable, keeping 17.9 cents of every revenue dollar as net income versus 10.1 cents for Smith & Nephew SNATS.
- DexCom grew revenue faster in its latest fiscal year (+15.60% vs +6.09%).
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Healthcare · Medical Devices · 11,000 employees
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Healthcare · Medical Devices · 17,000 employees
DXCM vs SNN FAQ
Which is bigger, DexCom or Smith & Nephew SNATS?
DexCom (DXCM) is larger, with a market capitalization of $31.85B compared with $11.28B for Smith & Nephew SNATS (SNN).
Which stock has performed better over the past year, DXCM or SNN?
DXCM returned +24.54% over the past 12 months, compared with -24.97% for SNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXCM or SNN?
SNN has the lower trailing P/E at 18.3, versus 33.5 for DXCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, DexCom or Smith & Nephew SNATS?
Smith & Nephew SNATS pays a dividend yielding 1.47%, while DexCom does not currently pay a regular dividend.
Are DexCom and Smith & Nephew SNATS in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.